Skip to main content
OpenTrials
Completed

NCT Number: NCT01402245

Targeting of Immune Response After Pneumococcal Vaccination

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pneumococcal Pneumonia Bacterial Infections Bacterial Infections and Mycoses Gram-Positive Bacterial Infections Infections Lung Diseases Pneumococcal Infections Pneumonia Pneumonia, Bacterial Pneumonia, Pneumococcal Respiratory Tract Diseases Respiratory Tract Infections Streptococcal Infections

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Division of Infectious Diseases, HUCH, Helsinki, Finland

Loading trial locations.

About this study

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study compares the homing profiles of Pnc-specific plasmablasts in 15 patients with pneumonia and in 15 volunteers receiving Pnc polysaccharide vaccine (PPV) and 12 volunteers receiving Pnc conjugate vaccine (PCV)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females ≥ 18 and <65 years of age.
  • General good health.
  • Written informed consent.
  • No previous vaccination against Pnc
  • No previous history of Pnc pneumonia
  • In pneumonia: Diagnosis of Pnc pneumonia within a week

Exclusion criteria

  • < 18 years, ≥65 of age.
  • In vaccinees: Acute disease at the time of enrollment.
  • Pregnancy or lactation.
  • Known immunodeficiency or immune suppressive treatment.
  • Any chronic illness that might interfere with the immune response
  • Alcohol or drug abuse
  • Any clinically significant history of known or suspected anaphylaxis or hypersensitivity (based on the investigator's judgement).

Treatment and study plan

Pneumococcal polysaccharide vaccine

Biological

Pneumococcal polysaccharide vaccine 0.5 ml i.m.

Other names: Pneumovax

pneumococcal conjugate vaccine

Biological

pneumococcal conjugate vaccine 0.5 ml i.m.

Other names: Prevenar

Primary outcomes

  1. Expression of homing receptors on circulating plasmablasts in Pnc pneumonia and after vaccination

    Time frame: Day 0 and Day 7-10

    HR on circulating Pnc-specific plasmablasts are determined in patients with pneumonia on day 7-10, in vaccinees on days 0 and 7

Sponsors and collaborators

Lead sponsor

Helsinki University Central Hospital

Other

Registry information

Official study title

Comparison of Immune Response in Pneumococcal Pneumonia and After Vaccination

Acronym: PncHR

Important dates

Study start
2005
Primary completion
2010
Study completion
2010
First posted
Jul 26, 2011
Registry last updated
Jul 26, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.